Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$68.65+1.6%$65.00$1.16▼$14.10$2.97B-0.12189,291 shs378,750 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics+1.57%+2.07%+4.30%-12.36%+61.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMTXGemini Therapeutics$68.65+1.6%$65.00$1.16▼$14.10$2.97B-0.12189,291 shs378,750 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMTXGemini Therapeutics+1.57%+2.07%+4.30%-12.36%+61.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMTXGemini Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGMTXGemini TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMTXGemini TherapeuticsN/A71.4971.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMTXGemini Therapeutics75.42%Insider OwnershipCompanyInsider OwnershipGMTXGemini Therapeutics12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableGMTX HeadlinesRecent News About These CompaniesGemini Therapeutics (NASDAQ:GMTX) Stock Price Down 0% - Time to Sell?May 1, 2026 | marketbeat.comGemini Therapeutics (NASDAQ:GMTX) Stock Price Up 1.6% - Still a Buy?April 10, 2026 | marketbeat.comFDA reversals leave investors worrying about the fates of other experimental drugsMarch 6, 2026 | cnbc.comWhat Is Gemini? Everything You Should Know About Google's AI ToolOctober 17, 2024 | cnet.comGoogle Gemini could soon get a lot more useful on your phoneJuly 31, 2024 | androidpolice.comAGemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?July 22, 2024 | businessinsider.comChatGPT vs. Microsoft Copilot vs. Gemini: Which is the best AI chatbot?May 23, 2024 | zdnet.comZGemini Monthly Horoscope: May 2024May 2, 2024 | pedestrian.tvPGoogle's Gemini AI Will Work On Your Pixel 2 XL—Android 10, 11 Devices Now SupportedApril 28, 2024 | techtimes.comTComparing ChatGPT 3.5, Microsoft Bing, and Google Gemini in diagnosing cases of neuro-ophthalmologyApril 17, 2024 | ophthalmologytimes.comOGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysApril 17, 2024 | seekingalpha.comGoogle takes down Gemini AI image generator. Here’s what you need to know.February 26, 2024 | washingtonpost.com‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiascoFebruary 26, 2024 | nypost.comNGoogle Gemini: Everything you need to know about Google's Answer to ChatGPT – Updated December 2023December 9, 2023 | androidheadlines.comAGemini Review 2023: Pros, Cons and How It ComparesNovember 16, 2023 | nerdwallet.comNYesterday's Gemini HoroscopeOctober 5, 2023 | yourtango.comYGemini Tarot Horoscopes: October 2023October 3, 2023 | glamour.comGYearly Gemini Tarot Card ReadingAugust 28, 2023 | yourtango.comYMove over Bard, Google's next big AI product is coming this fallAugust 19, 2023 | androidauthority.comARadar In Space: The Gemini Rendezvous RadarJuly 27, 2023 | hackaday.comHSun Transit in Gemini- The twins love the Sun’s visitJuly 13, 2023 | prokerala.comPGMTX Company DescriptionsGemini Therapeutics NASDAQ:GMTX$68.65 +1.06 (+1.57%) As of 05/6/2026Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally IonQ Just Posted a Breakout Quarter—But 1 Problem Remains Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
